November 25th, 2013
Last month we reported that the FDA’s advisory panel had unanimously voted in favour of approving the treatment.
Data from clinical trials showed that the hep C virus could not be detected in about 8 in 10 patients after treatment with the drug.
The FDA is also expected to make an announcement before 8 December on whether to formally approve Gilead Science’s treatment sofosbuvir.
Hep C affects an estimated 3.2 million people in the US.
Photo by Rosalynn Rambles